In the 4th TimePie Longevity Forum, Professor Andrea Maier shared with us the evidence-based interventions to prolong health and lifespan in humans. She introduced multiple biological clocks and covered the promising anti-aging supplements in her speech.
Professor Maier serves at the National University of Singapore as Co-Director of the Centre for Healthy Longevity as well as the President of the Australian and New Zealand Society for Sarcopenia and Frailty Research. Her research focuses on unraveling the mechanisms of ageing and age-related diseases. During the last 10 years she has conducted multiple international observational studies and intervention trials and has published more than 300 peer-reviewed articles, achieving an H index of 54.
00:05 Introduction
03:18 Goals of establishing the longevity ecosystem
05:37 What’s the definition of healthspan
09:15 Framework for aging biomarkers
13:26 Creation of body clock and organ-specific clocks
17:24 Using glucose monitoring systems to track patients
18:27 Interventions of nutrients, supplements, and food
19:12 How NMN can influence aged people
20:44 Experiments on AKG
22:38 Reviews on Rapamycin and Rapalogs
23:42 Invitation to Singapore Longevity Clinic
24:55 Q&A session
The rapamycin paper she mentions in the talk that her group recently came out with is this one: Big Review paper: Targeting ageing with rapamycin and its derivatives in humans (LancetLongevity)
3 Likes
This was very interesting. I continue to be whiplashed by the “we don’t know very much yet” and presentations like this that look like they are just in the edge of incredible breakthroughs. For now I’ll assume these are just very good sales pitches, and I’ll wait for the big news to drop….if it drops.
1 Like
Related:
Evelyn Yehudit Bischof |
Healthy Longevity Medicine in the Clinical Practice - Optimizing the Healthspan Along the Lifespan, Creating Guidelines and Shaping a New Medical Discipline
Prof. Evelyne Bischof, MD, MPH, FEFIM spent over a decade practicing medicine, while also lecturing at medical schools and performing clinical and translational research in Boston, New York, Shanghai and Basel, with extensive experience in scientific research and clinical practice at the following well-known and highly reputable institutions: University Hospital of Basel, Fudan Cancer Institute and Hospital; Zhongshan Hospital, Renji Hospital and Shanghai East Hospital. EB sits on several scientific and advisory boards of biotech and longevity hubs. Currently also affiliated with the Centre of Healthy Aging, Universität Zürich, and prev. senior attending physician of internal medicine at the University Hospital Basel. Swiss board certified as internal medicine specialist (FMH), trained in Europe, USA and China (Harvard Medical School affiliated hospitals (Mass General Hospital, Beth Israel MD, Dana Farber Institute) and Columbia University NYC; Fudan University hospitals, Shanghai and University Hospitals of Zurich and Basel (Switzerland).
Longevity Medicine is a burgeoning discipline that is uniquely rapidly evolving, fueled by the progress in geroscience, in AI/biotech, and in medicine as a whole, including virtually all disciplines. Moreover, it continuously adds the most advanced personalized approaches, such as multi-omics, AI, deep aging biomarkers, precision imaging, aging clocks, robotics, smart technologies to the assortment. This enormous pace and granularity demand an intensive acceleration of the translation from basic science towards the clinic, as well as a parallel, continued credible education for practicing physicians. In order to position longevity medicine as a solid clinical and academic discipline, it is incumbent to facilitate an interdisciplinary dialogue and on bridging the gap between health care providers and interdisciplinary experts such as academic biogerontologists, AI experts, computer scientists, peer-reviewed targeted publishing venues, and KOLs.
Related:
1 Like
